title: Naturally occurring, tumor-specific, therapeutic proteins.
abstract: The emerging approach to cancer treatment known as targeted therapies offers hope in improving the treatment of therapy-resistant cancers. Recent understanding of the molecular pathogenesis of cancer has led to the development of targeted novel drugs such as monoclonal antibodies, small molecule inhibitors, mimetics, antisense and small interference RNA-based strategies, among others. These compounds act on specific targets that are believed to contribute to the development and progression of cancers and resistance of tumors to conventional therapies. Delivered individually or combined with chemo- and/or radiotherapy, such novel drugs have produced significant responses in certain types of cancer. Among the most successful novel compounds are those which target tyrosine kinases (imatinib, trastuzumab, sinutinib, cetuximab). However, these compounds can cause severe side-effects as they inhibit pathways such as epidermal growth factor receptor (EGFR) or platelet-derived growth factor receptor, which are also important for normal functions in non-transformed cells. Recently, a number of proteins have been identified which show a remarkable tumor-specific cytotoxic activity. This toxicity is independent of tumor type or specific genetic changes such as p53, pRB or EGFR aberrations. These tumor-specific killer proteins are either derived from common human and animal viruses such as E1A, E4ORF4 and VP3 (apoptin) or of cellular origin, such as TRAIL (tumor necrosis factor-related apoptosis-inducing ligand) and MDA-7 (melanoma differentiation associated-7). This review aims to present a current overview of a selection of these proteins with preferential toxicity among cancer cells and will provide an insight into the possible mechanism of action, tumor specificity and their potential as novel tumor-specific cancer therapeutics.
authors.affiliation: ENT Department, Broomfield Hospital, Chelmsford, Essex, UK.
authors.forename: Konstantinos
authors.initials: K
authors.lastname: Argiris
authors.forename: Chrysoula
authors.initials: C
authors.lastname: Panethymitaki
authors.forename: Mahvash
authors.initials: M
authors.lastname: Tavassoli
mesh_terms: D017209:Apoptosis; D006801:Humans; D007768:Lactalbumin / Q000627:therapeutic use; D009369:Neoplasms / Q000188:drug therapy* / Q000473:pathology; D009928:Organ Specificity; D011506:Proteins / Q000627:therapeutic use*; D053221:TNF-Related Apoptosis-Inducing Ligand / Q000627:therapeutic use
chemical_list: D011506:Proteins; D053221:TNF-Related Apoptosis-Inducing Ligand; D007768:Lactalbumin